Abstract
Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 85-91 |
| Number of pages | 7 |
| Journal | Selective Cancer Therapeutics |
| Volume | 7 |
| Issue number | 2 |
| State | Published - 1991 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
Cite this
Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule. / Cobb, P. W.; Havlin, K. A.; Kuhn, J. G.; Craig, J. B.; Harman, G. S.; Luther, J. S.; Turner, J. N.; Weiss, G. R.; Tweedy, D. A.; Koeller, J.; Tuttle, R. L.; Lucas, V. S.; Wargin, W.
In: Selective Cancer Therapeutics, Vol. 7, No. 2, 1991, p. 85-91.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule
AU - Cobb, P. W.
AU - Havlin, K. A.
AU - Kuhn, J. G.
AU - Craig, J. B.
AU - Harman, G. S.
AU - Luther, J. S.
AU - Turner, J. N.
AU - Weiss, G. R.
AU - Tweedy, D. A.
AU - Koeller, J.
AU - Tuttle, R. L.
AU - Lucas, V. S.
AU - Wargin, W.
PY - 1991
Y1 - 1991
N2 - Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.
AB - Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a phase I trial using a monthly six-hour infusion schedule the recommended dose for future phase II trials was found to be 388 mg/m2. Neurologic toxicity was dose-limiting in that trial and correlated with the attainment of a threshold plasma concentration of >4.5 μg/ml. In this study we treated 15 patients with escalating doses of crisnatol from 450 mg/m2 to 900 mg/m2 administered at a rate of 50 mg/m2/hr over 9, 12, 15, and 18 hours. Toxicity was mild to moderate at all dose levels. However, serious central nervous system effects were noted in one patient at 900 mg/m2 over 18 hours whose plasma level was 6.5 μg/ml. This study has demonstrated higher total doses of crisnatol can be given if the drug is administered as a prolonged infusion in an attempt to avoid high plasma levels of the agent.
UR - http://www.scopus.com/inward/record.url?scp=0025999604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025999604&partnerID=8YFLogxK
M3 - Article
C2 - 1754731
AN - SCOPUS:0025999604
VL - 7
SP - 85
EP - 91
JO - Selective Cancer Therapeutics
JF - Selective Cancer Therapeutics
SN - 1043-0733
IS - 2
ER -